Sinclair Pharma PLC (LON:SPH)‘s stock had its “buy” rating reiterated by investment analysts at Peel Hunt in a report released on Wednesday. They currently have a GBX 68 ($0.89) price objective on the specialty pharmaceutical company’s stock. Peel Hunt’s price target points to a potential upside of 151.85% from the stock’s previous close.

A number of other equities analysts also recently weighed in on the stock. Royal Bank Of Canada reaffirmed an “outperform” rating on shares of Sinclair Pharma PLC in a research note on Thursday, September 15th. Stifel Nicolaus raised their target price on shares of Sinclair Pharma PLC from GBX 49 ($0.64) to GBX 63 ($0.82) and gave the company a “buy” rating in a research note on Wednesday, September 14th. Finally, Jefferies Group decreased their target price on shares of Sinclair Pharma PLC from GBX 60 ($0.78) to GBX 55 ($0.72) and set a “buy” rating for the company in a research note on Wednesday, June 15th. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus target price of GBX 57 ($0.74).

Analyst Recommendations for Sinclair Pharma PLC (LON:SPH)

Shares of Sinclair Pharma PLC (LON:SPH) opened at 28.3125 on Wednesday. Sinclair Pharma PLC has a one year low of GBX 26.25 and a one year high of GBX 61.33. The company’s market cap is GBX 140.71 million. The firm’s 50-day moving average is GBX 29.84 and its 200-day moving average is GBX 32.69.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at

Sinclair Pharma PLC Company Profile

Sinclair Pharma plc, formerly Sinclair IS Pharma plc, is a United Kingdom-based specialty pharmaceutical company. The Company is engaged in the manufacture and wholesale distribution of dermatological products. Its segments are Country Operations, which include its operations in France, the United Kingdom, Italy, Germany and Spain, and International Operations, under which the Company sells through a local distributor.

Receive News & Ratings for Sinclair Pharma PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sinclair Pharma PLC and related companies with's FREE daily email newsletter.